Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized versus standard vancomycin dosing in neonates and young infants with late-onset sepsis
2015-000203-89Phase 2Terminated
- Sponsor
- Penta Foundation
- Start
- May 2016
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vancomycin in late-onset neonatal sepsis (LONS) and Bacterial sepsis (2 arms), sponsored by Penta Foundation. Primary endpoint: Successful outcome at test of cure visit. Started May 2016; status: terminated.
02
Drugs
vancomycin
03
Conditions
late-onset neonatal sepsis (LONS)Bacterial sepsis
Beyond the preview
Go deeper on 2015-000203-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000203-89.